Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Entresto US Sales Barriers Set To Be Removed By Strong Guidance

Executive Summary

Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.

Advertisement

Related Content

Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

Topics

Advertisement
UsernamePublicRestriction

Register